Stock CTH CYNAPSUS THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Cynapsus Therapeutics Inc Toronto S.E.

Equities

CTH

CA23257Y7019

End-of-day quote Toronto S.E.
Other stock markets
- CAD - Intraday chart for Cynapsus Therapeutics Inc
Mar. 11 Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA MT
Jan. 29 CoTec Holdings Outlines Key Targets For 2024 MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics
PU
Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
GL
Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration
GL
Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease
GL
Cynapsus Therapeutics : Reports Second Quarter 2016 Financial Results and Recent Developments
GL
Cynapsus Therapeutics : Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
GL
Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
GL
Cynapsus Therapeutics : Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
GL
Cynapsus Therapeutics : Announces 2016 Analyst and Investor Day
GL
Cynapsus Therapeutics Announces 2016 Analyst and Investor Day
GL
Cynapsus Therapeutics : Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients with Parkinson's Disease
GL
Cynapsus Therapeutics Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients with Parkinson’s Disease
GL
Cynapsus Therapeutics Announces Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders
GL
Cynapsus Therapeutics : Announces Data Presentations at the European Academy of Neurology Annual Meeting
GL
Cynapsus Therapeutics Announces Data Presentations at the European Academy of Neurology Annual Meeting
GL
Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors
GL
Cynapsus Therapeutics Reports First Quarter 2016 Financial Results and Recent Developments
GL
Cynapsus Therapeutics Announces Results of AGM
GL
Cynapsus Therapeutics to Present at Several Upcoming Investor Conferences
GL
Cynapsus Therapeutics : Announces Data Presentations at the American Academy of Neurology Annual Meeting
MW
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CTH Stock
  4. CTH Stock
  5. News Cynapsus Therapeutics Inc
  6. Press Releases